Clinical trials: Branch Retinal Vein Occlusion (BRVO)
Branch Retinal Vein Occlusion
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- NCT04667897
- Testing
- 601 1.25mg, Ranibizuman 0.5 mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
The aim of this study is to evaluate the visual outcome and prognostic factors after intraocular injections of Bevacizumab or combination of Bevacizumab And Dexamethasone under pro re nata treatment regimen for Branch Retinal…
- Trial name
- NCT04601688
- Testing
- Bevacizumab Ophthalmic and Intravitreal Dexamethasone, Bevacizumab Ophthalmic
- Where
- China
- Volunteers
- 100 people
- Sponsor
- He Eye Hospital
Branch Retinal Vein Occlusion
Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)
This study is designed to evaluate the efficacy of intravitreal Ranibizumab in comparison with macular laser photocoagulation as treatments for macular edema secondary to branch retinal vein occlusion.
- Trial name
- NCT01189526
- Testing
- Ranibizumab, macular laser photocoagulation
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul Retina Investigator Group
Macular Edema Secondary to Branch Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- Blossom (NCT01976338)
- Testing
- Ranibizumab 0.5 mg
- Where
- 33 sites in China, Hong Kong and 4 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Disease
Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
The study aims to collect data on the safety and use of intravitreal aflibercept injections into the eye for the treatment of eye disorders that cause blurred vision or a blind spot due to abnormal or blocked blood vessels.
- Trial name
- MAIA (NCT04137120)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- Mexico
- Volunteers
- 73 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
- Trial name
- Super Tuscan (NCT07205887)
- Testing
- Remigromig, Aflibercept 2.0 mg
- Where
- 55 sites in United States
- Volunteers
- 160 people
- Sponsor
- EyeBiotech Ltd.
Retinal Vein Occlusion
Ranibizumab in Patients With Branch Retinal Vein Occlusion
In a recent study we could show that the early retinal venous vasoconstriction after grid photocoagulation in branch retinal vein occlusion (BRVO) is closely correlated to the visual outcome after three months.
- Trial name
- NCT01027481
- Testing
- Lucentis
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO
This is an observational study in which data already collected from people with the eye disorders below are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- AIRSPEED (NCT06495203)
- Testing
- anti-VEGF treatment
- Where
- Canada
- Volunteers
- 1,350 people
- Sponsor
- Bayer
Branch Retinal Vein Occlusion, Macular Edema
Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
The purpose of this study is to determine whether pars plana vitrectomy in combination with triamcinolone acetate is effective in the treatment of macular edema due to branch retinal vein occlusion.
- Trial name
- NCT00642226
- Testing
- Grid Laser, Vitrectomy and 20 mg triamcinolone
- Where
- Norway
- Volunteers
- 34 people
- Sponsor
- Helse Stavanger HF
Branch Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
- Trial name
- RAPTOR (NCT03802630)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 102 sites in United States, Austria and 17 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Branch Retinal Vein Occlusion
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
To compare the efficacy and safety of recombinant humanized anti-VEGF monoclonal antibody (601) with Ranibizumab in patients with macular edema secondary to BRVO
- Trial name
- NCT05520177
- Testing
- 601 1.25mg, ranibizumab 0.5mg
- Where
- 10 sites in China
- Volunteers
- 351 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Branch Retinal Vein Occlusion, Retinal Blood Flow
Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects
Assessment of retinal vessel calibers combined with bidirectional Fourier domain optical coherence tomography (FDOCT) for measurement of retinal blood velocities is a new and sophisticated method for assessing retinal blood flow…
- Conditions
- Branch Retinal Vein Occlusion, Retinal Blood Flow, Retinal Oxygen Saturation
- Trial name
- NCT01746615
- Testing
- Dynamic Vessel Analyzer, Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)
- Where
- Austria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch…
- Trial name
- WAVE (NCT01710839)
- Testing
- 0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Charles C Wykoff, PhD, MD
Retinal Vein Occlusion, Macular Edema
Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
This was a prospective, single center, open label, randomized study evaluating the biological effect of squalamine lactate ophthalmic solution, 0.2% combined with intravitreous ranibizumab in patients with macular edema secondary…
- Trial name
- NCT02614937
- Testing
- ranibizumab, Squalamine Lactate Ophthalmic Solution, 0.2%
- Volunteers
- 20 people
- Sponsor
- Ohr Pharmaceutical Inc.
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular…
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT04516278
- Testing
- bevacizumab
- Where
- 20 sites in United States
- Volunteers
- 197 people
- Sponsor
- Outlook Therapeutics, Inc.
Branch Retinal Vein Occlusion With Macular Edema
Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO
To evaluate the efficacy of sequential therapy with intravitreal dexamethasone implant followed by bevacizumab compared with bevacizumab monotherapy for macular edema (ME) secondary to retinal vein occlusion (RVO).
- Trial name
- NCT03892434
- Testing
- Intravitreal bevacizumab and dexamethasone implant Injection, Intravitreal dexamethasone implant
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yeungnam University College of Medicine